help button home button Endocrine Society JCEM JCEM Call for Nominations for EIC
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hardouin, S.
Right arrow Articles by Binoux, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hardouin, S.
Right arrow Articles by Binoux, M.

Journal of Clinical Endocrinology & Metabolism, Vol 69, 1291-1301, Copyright © 1989 by Endocrine Society


ARTICLES

Molecular forms of serum insulin-like growth factor (IGF)-binding proteins in man: relationships with growth hormone and IGFs and physiological significance

S Hardouin, M Gourmelen, P Noguiez, D Seurin, M Roghani, Y Le Bouc, G Povoa, TJ Merimee, P Hossenlopp and M Binoux
Institut National de la Sante et de la Recherche Medicale, Unite 142, Hopital Trousseau, Paris, France.

Insulin-like growth factor-I (IGF-I) and IGF-II are associated in the blood with specific binding proteins (BPs), forming complexes that elute in gel filtration with estimated mol wt around 40 and 150 kD. The latter appears to be under GH control. Five molecular forms of BP (41.5, 38.5, 34, 30, and 24 kD) have been identified by Western blotting using 125I-labeled IGF. All five forms are present in the smaller complexes, but only the 41.5- and 38.5-kD forms are found in the larger complexes. In this study immunoblotting showed that the 41.5- and 38.5-kD forms were recognized by antibodies directed against the GH- dependent BP purified from human plasma, and the 30-kD form was recognized by antibodies directed against the BP purified from amniotic fluid. The 34- and 24-kD forms proved to be immunologically unrelated to the other three. In sera with large quantities of the 41.5- and 38.5- kD forms, an additional band was often observed immediately ahead of the migration front of the 30 kD band. This was recognized by the anti- GH-dependent BP antibody and probably corresponds to a degradation product of the 41.5- and 38.5-kD BPs. Serum 41.5- and 38.5-kD BPs have been found to be elevated in acromegaly, where GH hypersecretion causes increased IGF-I levels, and diminished in cases of genetic or idiopathic GH deficiency and defects of the GH receptor (Laron's syndrome), where both IGF-I and IGF-II are decreased, as well as in Pygmy adults and children who have isolated IGF-I deficiency. In all of these conditions, the proportions of the 34- and 30-kD forms were inversely related to those of the 41.5- and 38.5-forms. Under treatment, the BP profiles tended to return to normal. In cases of GH deficiency caused by a tumor, the BP profiles resembled those of hypopituitary or normal serum, depending on whether IGF levels were diminished or normal. It, therefore, seems that BP synthesis is coordinated with IGF-I synthesis and may not be directly GH dependent. The results of neutral pH gel filtration analysis of hypopituitary (idiopathic and tumoral) and normal sera point to a relationship between the levels of circulating IGFs and those of the 150-kD IGF-BP complex whose binding units are the 41.5- and 38.5-kD BPs. It, therefore, seems that the 150-kD complex controls the bioavailability of IGF-I and IGF-II.(ABSTRACT TRUNCATED AT 400 WORDS)


This article has been cited by other articles:


Home page
Endocr Relat CancerHome page
J. W. B de Groot, B. Rikhof, J. van Doorn, H. J G Bilo, M. A Alleman, A. H Honkoop, and W. T A van der Graaf
Non-islet cell tumour-induced hypoglycaemia: a review of the literature including two new cases
Endocr. Relat. Cancer, December 1, 2007; 14(4): 979 - 993.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
B. Ducos, S. Cabrol, M. Houang, L. Perin, M. Holzenberger, and Y. Le Bouc
IGF Type 1 Receptor Ligand Binding Characteristics Are Altered in a Subgroup of Children with Intrauterine Growth Retardation
J. Clin. Endocrinol. Metab., November 1, 2001; 86(11): 5516 - 5524.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
P. Chanson, F. Daujat, J. Young, A. Bellucci, M. Kujas, D. Doyon, and G. Schaison
Normal Pituitary Hypertrophy as a Frequent Cause of Pituitary Incidentaloma: A Follow-Up Study
J. Clin. Endocrinol. Metab., July 1, 2001; 86(7): 3009 - 3015.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
E. Baixeras, S. Jeay, P. A. Kelly, and M.-C. Postel-Vinay
The Proliferative and Antiapoptotic Actions of Growth Hormone and Insulin-Like Growth Factor-1 Are Mediated through Distinct Signaling Pathways in the Pro-B Ba/F3 Cell Line
Endocrinology, July 1, 2001; 142(7): 2968 - 2977.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
N. Kawai, S. Kanzaki, S. Takano-Watou, C. Tada, Y. Yamanaka, T. Miyata, M. Oka, and Y. Seino
Serum Free Insulin-Like Growth Factor I (IGF-I), Total IGF-I, and IGF-Binding Protein-3 Concentrations in Normal Children and Children with Growth Hormone Deficiency
J. Clin. Endocrinol. Metab., January 1, 1999; 84(1): 82 - 89.
[Abstract] [Full Text]


Home page
J. Clin. Endocrinol. Metab.Home page
A. Barreca, M. Bozzola, A. Cesarone, P. H. Steenbergh, P. E. Holthuizen, F. Severi, G. Giordano, and F. Minuto
Short Stature Associated with High Circulating Insulin-Like Growth Factor (IGF)-Binding Protein-1 and Low Circulating IGF-II: Effect of Growth Hormone Therapy
J. Clin. Endocrinol. Metab., October 1, 1998; 83(10): 3534 - 3541.
[Abstract] [Full Text]


Home page
Am. J. Physiol. Renal Physiol.Home page
M. J. Horney, D. W. Shirley, D. T. Kurtz, and S. A. Rosenzweig
Elevated glucose increases mesangial cell sensitivity to insulin-like growth factor I
Am J Physiol Renal Physiol, June 1, 1998; 274(6): F1045 - F1053.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
N. Boulle, A. Logié, C. Gicquel, L. Perin, and Y. Le Bouc
Increased Levels of Insulin-Like Growth Factor II (IGF-II) and IGF-Binding Protein-2 Are Associated with Malignancy in Sporadic Adrenocortical Tumors
J. Clin. Endocrinol. Metab., May 1, 1998; 83(5): 1713 - 1720.
[Abstract] [Full Text]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
T. J. Wester, T. A. Davis, M. L. Fiorotto, and D. G. Burrin
Exogenous growth hormone stimulates somatotropic axis function and growth in neonatal pigs
Am J Physiol Endocrinol Metab, January 1, 1998; 274(1): E29 - E37.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
S. Rajaram, D. J. Baylink, and S. Mohan
Insulin-Like Growth Factor-Binding Proteins in Serum and Other Biological Fluids: Regulation and Functions
Endocr. Rev., December 1, 1997; 18(6): 801 - 831.
[Abstract] [Full Text]


Home page
EndocrinologyHome page
Z. S. Gucev, Y. Oh, K. M. Kelley, J. I. Labarta, P. Vorwerk, and R. G. Rosenfeld
Evidence for Insulin-Like Growth Factor (IGF)-Independent Transcriptional Regulation of IGF Binding Protein-3 by Growth Hormone in SKHEP-1 Human Hepatocarcinoma Cells
Endocrinology, April 1, 1997; 138(4): 1464 - 1470.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
Y. J. H. Janssen, M. Frolich, and F. Roelfsema
A Low Starting Dose of Genotropin in Growth Hormone-Deficient Adults
J. Clin. Endocrinol. Metab., January 1, 1997; 82(1): 129 - 135.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
K. A. Woods, C. Camacho-Hubner, M. O. Savage, and A. J.L. Clark
Intrauterine Growth Retardation and Postnatal Growth Failure Associated with Deletion of the Insulin-Like Growth Factor I Gene
N. Engl. J. Med., October 31, 1996; 335(18): 1363 - 1367.
[Full Text] [PDF]


Home page
Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
V. Besnard, E. Nabeyrat, A. Henrion-Caude, K. Chadelat, L. Perin, Y. Le Bouc, and A. Clement
Protective role of retinoic acid from antiproliferative action of TNF-alpha on lung epithelial cells
Am J Physiol Lung Cell Mol Physiol, April 1, 2002; 282(4): L863 - L871.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1989 by The Endocrine Society